Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
Zacks News
Teva Settles With Oklahoma, Shares Fall Following Downgrade
by Zacks Equity Research
Teva (TEVA) plummets after settlement with the state of Oklahoma in a litigation related to its role in opioid epidemic, resulting in a rating downgrade.
Company News For May 29, 2019
by Zacks Equity Research
Companies in the news are: UBER, TEVA, AMD and ASGN
Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL
by Zacks Equity Research
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer
Company News For May 14, 2019
by Zacks Equity Research
Companies in the news are: TEVA, FF, PM and KRNT
The Zacks Analyst Blog Highlights: Teva, Amazon, Berkshire and JPMorgan
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Teva, Amazon, Berkshire and JPMorgan
Generic Drugmakers Face Antitrust Suit Alleging Price Fixing
by Kinjel Shah
Shares of generic drugmakers decline on allegations of price fixing by 44 states.
States Expand Suit Against Teva & Others, Shares Plunge
by Sejuti Banerjea
Teva Lawsuit scratches the surface of a much bigger price fixing racket in pharmaceuticals.
Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Mylan's (MYL) earnings beat estimates but sales miss the same in the first quarter of 2019.
BioDelivery (BDSI) Stock Up on Q1 Earnings and Sales Beat
by Zacks Equity Research
BioDelivery (BDSI) incurs narrower-than-expected loss in Q1. Sales surpass the consensus mark. The company raises guidance for 2019.
Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View
by Zacks Equity Research
Allergan's (AGN) stock declines slightly in pre-market trading despite the company delivering earnings and revenue beat in the first quarter while marginally raising its guidance
Mylan (MYL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on the performance of Wixela Inhub, the newly launched biosimilars and other updates from Mylan (MYL)'s pipeline when the company shortly reports Q1 results.
Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down
by Zacks Equity Research
Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.
Teva (TEVA) Beats on Q1 Earnings, Misses Sales, Shares Down
by Kinjel Shah
Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Shares decline in pre-market trading.
Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut
by Zacks Equity Research
Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.
Teva (TEVA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q1.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $15.14, marking a +0.93% move from the previous day.
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on sales growth.
Allergan Falls as Supreme Court Dismisses Restasis Litigation
by Zacks Equity Research
Allergan's (AGN) key drug, Restasis' prospects hurt as the U.S. Supreme Court upholds the ruling of a lower court, which invalidated certain patents protecting the drug.
BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M
by Zacks Equity Research
BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU
by Kinjel Shah
Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig
by Zacks Equity Research
Novartis (NVS) sues Amgen as the latter issues termination notice for migraine drug.
Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe
by Zacks Equity Research
Teva's (TEVA) CGRP injection, Ajovy gets marketing approval in the EU after securing approval in the United States last year.
Novartis (NVS) Receives FDA Approval for MS Drug Mayzent
by Zacks Equity Research
Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.